JP2004516236A - 抗血栓剤 - Google Patents

抗血栓剤 Download PDF

Info

Publication number
JP2004516236A
JP2004516236A JP2001583806A JP2001583806A JP2004516236A JP 2004516236 A JP2004516236 A JP 2004516236A JP 2001583806 A JP2001583806 A JP 2001583806A JP 2001583806 A JP2001583806 A JP 2001583806A JP 2004516236 A JP2004516236 A JP 2004516236A
Authority
JP
Japan
Prior art keywords
factor
antibody
seq
antibodies
mab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001583806A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004516236A5 (https=
Inventor
フランク・シー・バローン
マイケル・エヌ・ブラックバーン
ジオラ・ゼット・フューアースタイン
ジョン・アール・トゥーメイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of JP2004516236A publication Critical patent/JP2004516236A/ja
Publication of JP2004516236A5 publication Critical patent/JP2004516236A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
JP2001583806A 2000-05-15 2000-10-05 抗血栓剤 Pending JP2004516236A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57143400A 2000-05-15 2000-05-15
PCT/US2000/027438 WO2001087339A1 (en) 2000-05-15 2000-10-05 Antithrombotic agents

Publications (2)

Publication Number Publication Date
JP2004516236A true JP2004516236A (ja) 2004-06-03
JP2004516236A5 JP2004516236A5 (https=) 2007-11-22

Family

ID=24283688

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001583806A Pending JP2004516236A (ja) 2000-05-15 2000-10-05 抗血栓剤

Country Status (20)

Country Link
US (1) US20050037006A1 (https=)
EP (2) EP1282444B1 (https=)
JP (1) JP2004516236A (https=)
KR (2) KR20070116192A (https=)
CN (2) CN100339132C (https=)
AT (1) ATE345816T1 (https=)
AU (2) AU2000278584B2 (https=)
BR (1) BR0015872A (https=)
CA (1) CA2411369A1 (https=)
CZ (1) CZ20023778A3 (https=)
DE (1) DE60032029T2 (https=)
ES (1) ES2277597T3 (https=)
HU (1) HU225874B1 (https=)
IL (1) IL152831A0 (https=)
MX (1) MXPA02011385A (https=)
NO (1) NO20025463L (https=)
NZ (1) NZ522632A (https=)
PL (1) PL360060A1 (https=)
WO (1) WO2001087339A1 (https=)
ZA (1) ZA200209265B (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008513447A (ja) * 2004-09-18 2008-05-01 ユニバーシティ オブ メリーランド， ボルチモア ＮＣＣａ−ＡＴＰチャネルを標的とする治療剤およびその使用方法
US8318810B2 (en) 2002-03-20 2012-11-27 University Of Maryland, Baltimore Methods for treating neural cell swelling
US8557867B2 (en) 2007-06-22 2013-10-15 The United States Of America As Represented By The Department Of Veterans Affairs Inhibitors of NCCa-ATP channels for therapy
US8569377B2 (en) 2004-09-18 2013-10-29 The United States Of America As Represented By The Department Of Veteran Affairs Methods for treating spinal cord injury with a compound that inhibits a NCCA-ATP channel
US8980952B2 (en) 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
US9511075B2 (en) 2007-01-12 2016-12-06 The University Of Maryland, Baltimore Targeting NCCA-ATP channel for organ protection following ischemic episode

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
PT3002298T (pt) * 2007-11-21 2019-11-20 Univ Oregon Health & Science Anticorpos monoclonais anti-fator xi e métodos de utilização dos mesmos
GB201121513D0 (en) * 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof
US9518128B2 (en) 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
CN110325211A (zh) * 2016-12-23 2019-10-11 诺华股份有限公司 采用抗因子XI/XIa抗体治疗的方法
US20200109390A1 (en) 2017-04-27 2020-04-09 Chugai Seiyaku Kabushiki Kaisha Coagulation factor ix with improved pharmacokinetics
US20240018503A1 (en) * 2017-04-27 2024-01-18 Chugai Seiyaku Kabushiki Kaisha Coagulation factor ix with improved pharmacokinetics
CN115448985A (zh) * 2021-06-08 2022-12-09 上海循曜生物科技有限公司 新型抗栓抗体

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000007626A1 (en) * 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
WO2000012562A1 (en) * 1998-08-28 2000-03-09 Genentech, Inc. HUMAN ANTI-FACTOR IX/IXa ANTIBODIES
JP2000503210A (ja) * 1996-01-17 2000-03-21 スミスクライン・ビーチャム・コーポレイション 血栓症治療において有用な抗凝固剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2049655C (en) * 1990-09-17 1996-11-12 Akio Odawara Pharmaceutical composition for inhibiting platelet aggregation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000503210A (ja) * 1996-01-17 2000-03-21 スミスクライン・ビーチャム・コーポレイション 血栓症治療において有用な抗凝固剤
WO2000007626A1 (en) * 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
WO2000012562A1 (en) * 1998-08-28 2000-03-09 Genentech, Inc. HUMAN ANTI-FACTOR IX/IXa ANTIBODIES

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8980952B2 (en) 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
US8318810B2 (en) 2002-03-20 2012-11-27 University Of Maryland, Baltimore Methods for treating neural cell swelling
US10533988B2 (en) 2002-03-20 2020-01-14 University Of Maryland, Baltimore Methods for treating central or peripheral nervous system damage
US9107932B2 (en) 2002-03-20 2015-08-18 University Of Maryland, Baltimore Methods for treating neural cell swelling
US8569377B2 (en) 2004-09-18 2013-10-29 The United States Of America As Represented By The Department Of Veteran Affairs Methods for treating spinal cord injury with a compound that inhibits a NCCA-ATP channel
JP2008513447A (ja) * 2004-09-18 2008-05-01 ユニバーシティ オブ メリーランド， ボルチモア ＮＣＣａ−ＡＴＰチャネルを標的とする治療剤およびその使用方法
US10583094B2 (en) 2004-09-18 2020-03-10 University Of Maryland Therapeutic methods that target the NCCA-ATP channel
US9511075B2 (en) 2007-01-12 2016-12-06 The University Of Maryland, Baltimore Targeting NCCA-ATP channel for organ protection following ischemic episode
US10166244B2 (en) 2007-01-12 2019-01-01 University Of Maryland, Baltimore Targeting NCCA-ATP channel for organ protection following ischemic episode
US10898496B2 (en) 2007-01-12 2021-01-26 University Of Maryland, Baltimore Targeting NCCa-ATP channel for organ protection following ischemic episode
US12121526B2 (en) 2007-01-12 2024-10-22 The United States Government As Represented By The Department Of Veterans Affairs Targeting NCCA-ATP channel for organ protection following ischemic episode
US9375438B2 (en) 2007-06-22 2016-06-28 University Of Maryland, Baltimore Inhibitors of NCCa-ATP channels for therapy
US8557867B2 (en) 2007-06-22 2013-10-15 The United States Of America As Represented By The Department Of Veterans Affairs Inhibitors of NCCa-ATP channels for therapy

Also Published As

Publication number Publication date
IL152831A0 (en) 2003-06-24
EP1282444A1 (en) 2003-02-12
BR0015872A (pt) 2004-08-03
CN101134107A (zh) 2008-03-05
WO2001087339A1 (en) 2001-11-22
ZA200209265B (en) 2003-10-22
CA2411369A1 (en) 2001-11-22
NO20025463L (no) 2003-01-09
CN100339132C (zh) 2007-09-26
KR20030034071A (ko) 2003-05-01
EP1282444A4 (en) 2004-06-30
HUP0301804A3 (en) 2005-12-28
DE60032029T2 (de) 2007-05-31
EP1825864A2 (en) 2007-08-29
CN1501812A (zh) 2004-06-02
HUP0301804A2 (hu) 2003-08-28
ATE345816T1 (de) 2006-12-15
NO20025463D0 (no) 2002-11-14
US20050037006A1 (en) 2005-02-17
NZ522632A (en) 2005-05-27
MXPA02011385A (es) 2004-01-26
AU7858400A (en) 2001-11-26
DE60032029D1 (de) 2007-01-04
EP1825864A3 (en) 2007-09-12
PL360060A1 (en) 2004-09-06
CZ20023778A3 (cs) 2003-08-13
EP1282444B1 (en) 2006-11-22
HU225874B1 (en) 2007-11-28
ES2277597T3 (es) 2007-07-16
AU2000278584B2 (en) 2006-11-16
KR20070116192A (ko) 2007-12-06

Similar Documents

Publication Publication Date Title
US6391299B1 (en) Anti-factor IX/IXa antibodies
EP2297207B1 (en) Use of anti-factor xi antibodies for prevention or treatment of thrombus formation
JP2004516236A (ja) 抗血栓剤
AU2000278584A1 (en) Antithrombotic agents
US20040146511A1 (en) Antithrombotic agents
US20060057140A1 (en) Anticoagulant agents useful in treatment of thrombosis
US20070190059A1 (en) Antithrombotic agents
HK1109339A (en) Antithrombotic agents
HK1029513B (en) Anticoagulant humanised antibodies against factor ix, for use in the treatment of thrombosis
HK1107932A (en) Anticoagulant agents useful in treatment of thrombosis
CA2243236A1 (en) Anticoagulant agents useful in treatment of thrombosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071004

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100907

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110308